BP8
Asset Logo

Bph Global Ltd

๐Ÿ‡ฆ๐Ÿ‡บ ASX

๐Ÿงฌ BIOTECHNOLOGY

Compare
Add to watchlist
๐Ÿ‘‘ Overview

๐Ÿ“ˆ Performance

๐Ÿ’ต Cost

๐Ÿค“ Advanced

๐Ÿ‘จโ€๐Ÿ‘ฉโ€๐Ÿ‘งโ€๐Ÿ‘ฆ Community

๐Ÿ“ˆ

-15.75%
Annual Growth

5 years average annual growth

๐Ÿ’ต

$ 500
Minimum Order

Due to regulatory requirements

๐ŸŒ

0
Pearlers Invested

Since January 2020

๐Ÿ‘‘ Overview

Key information
๐Ÿ”Ž Fund Overview

BPH Global Ltd. is a plant-based biotechnology company, which engages in the business of sourcing, producing, marketing, and selling traditional medicines. The company is headquartered in Melbourne, New South Wales. The company went IPO on 2000-06-13. The firm is focused on producing foods and products that deliver Traditional Chinese Medicine-based health outcomes. The company focuses on the research and development, production and commercialization of plant-based products, including seaweed and sea plants to produce sustainable plant-based protein foods and nutraceutical and pharmaceutical ingredients (including cannabidiol (CBD) extracted from Hemp) for utilization in the food, nutrition, healthcare, cosmetics, and personal care industries. Its principal business focus is on Singapore, Australia, Southeast Asia, and Chinese markets. The firm produces its products through various plants, which include Caulerpa lentillifera, Dendrobium officinale, Resina and Cannabis sativa. The company is also into the sales and distribution of bird's nest products in China. Its subsidiaries include Stemcell United Pte Ltd, Stemcell Essential Pte Ltd, and SCU Southeast Asia Sdn Bhd, SCU (HK) Ltd.

๐Ÿ“ˆ Performance

Price History

-99.80%

1M

1Y

10Y

Graph

Table

Unsure how much or often to invest?
๐Ÿ—“๏ธ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out โ†’
๐Ÿ’ต Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out โ†’
โฑ๏ธ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out โ†’

๐Ÿ’ต Costs

๐Ÿ’ต

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

๐Ÿ’ผ

N/A
Management Fee

Included in unit price, not charged by Pearler

๐Ÿ’ธ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
๐Ÿ’ธ Net fee calculator

๐Ÿค“ Advanced information

Technical Info

๐Ÿ’ฐ Price*

$0.00

*Price may be up to 24 hours old

๐Ÿ‘ฉโ€๐Ÿ‘ฉโ€๐Ÿ‘ฆ Community Insights

How our community is investing

๐ŸŒ Pearlers invested in BP8

0

๐Ÿ“Š Total Capital Earnings

N/A

๐Ÿ”ƒ Average investment frequency

N/A

๐Ÿ’ต Average investment amount

N/A

โฐ Last time a customer invested in BP8

N/A
BP8 investor breakdown
๐Ÿ’ต Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

๐Ÿ‘ถ Age of investors

18 - 25

26 - 34

35 - 90

๐Ÿ™‹ Legal gender of investors

Female

Male

Pearlers who invest in BP8 also invest in...

Want more shares? Try these...

Bph Global Ltd

BP8O

๐Ÿ“Š Share price

$0.00 AUD
Find Out More

BPH Energy Ltd. engages in investments in biotechnology and oil and gas exploration entities. The company is headquartered in Perth, Western Australia. The company went IPO on 2004-08-06. The firm holds a significant interest in an unlisted oil and gas exploration company. The Companyโ€™s principal activities include investments in various companies, which include Clean Hydrogen Technologies Corporation (Clean Hydrogen Technologies), Cortical Dynamics Limited (Cortical), Advent Energy Limited, and Molecular Discovery Systems Limited (MDSystems). Clean Hydrogen Technologies is a USA Delaware registered company with technology to produce clean hydrogen. The Advent Energy Limited is an unlisted oil and gas exploration and production company based in Perth, Western Australia. The Cortical is a medical device company focused on developing brain function monitors by employing theories and technologies in the field. MDSystems focuses on drug discovery and the validation of biomarkers for disease, therapy and diagnostics.

๐Ÿ™Œ Performance (5Yr p.a)

110.00%

๐Ÿ“Š Share price

$0.01 AUD

๐Ÿ’ธ FINANCIALS

Bank of Queensland Ltd. engages in the provision of financial services to the community. The company is headquartered in Brisbane, Queensland and currently employs 3,169 full-time employees. The Companyโ€™s operating segments include Retail Banking and BOQ Business. The Retail Banking segment provides retail banking solutions to customers through its owner-managed and corporate branch network, third-party intermediaries, and virgin money distribution channels. Its Owner-Managed Branches retail and small and medium enterprises (SME) lending, deposits, credit cards and insurance. Its VMA business include digital home loans, deposits, credit cards, insurance, and superannuation. The BOQ Business segment includes the BOQ branded commercial lending activity, BOQ Finance and BOQ Specialist businesses. The company also provides tailored business banking solutions, including commercial lending, equipment finance and leasing, cashflow finance, foreign exchange, interest rate hedging, transaction banking and deposit solutions for commercial customers. The company operates more than 160 branches across Australia.

๐Ÿ“Š Share price

$105.03 AUD

๐Ÿฆ BANKING

Botanix Pharmaceuticals Ltd. is a dermatology company, which engages in the business of researching and developing dermatology and antimicrobial products. The company is headquartered in Leederville, Western Australia. The firm is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. The company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. The company also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.

๐Ÿ™Œ Performance (5Yr p.a)

36.52%

๐Ÿ“Š Share price

$0.33 AUD

๐Ÿ“ฆ LOGISTICS

๐Ÿ“ˆ HIGH PRICE GROWTH

Compare
Add to watchlist